NEW YORK, Jan. 21, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Endometriosis in US$ Million.
Read the full report: https://www.reportlinker.com/p04368326
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World.
Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 38 companies including many key and niche players such as:
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Debiopharm Group
- Evotec AG
Read the full report: https://www.reportlinker.com/p04368326
ENDOMETRIOSIS MCP-6
MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
Endometriosis: An Introductory Prelude
Endometriosis Facts in a Nutshell
Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
Key Endometriosis Drugs on the Market
Table 1: Leading Endometriosis Drugs on the Market (2017E): Percentage Breakdown of Revenues for Depo-Provera, Lupron, Visanne, Zoladex and Others (includes corresponding Graph/Chart)
The Pipeline Review
Key Endometriosis Drugs in the Pipeline: 2017
Steady Growth Expected Over the Next Few Years
Emerging Treatment for Endometriosis & Endometrial Cancer
Global Awareness Campaigns and Efforts
Uptrend in Healthcare Expenditure Creates Substantial Opportunities
Table 2: Healthcare Spending as % of GDP by Geographic Region (2016) (includes corresponding Graph/Chart)
Table 3: Per Capita Healthcare Spending (in $) in Select Developed Countries for the Year 2016 (includes corresponding Graph/Chart)
Developed Regions Remain Primary Revenue Contributors
Table 4: Developed Regions Account for over 90% Share of World Endometriosis Drugs Market: Percentage Breakdown of Value Sales for Developed Regions and Developing Regions (2017E & 2022P) (includes corresponding Graph/Chart)
Developing Regions Exhibit Immense Growth Potential
Stable Economic Scenario to Augment Market Prospects
Table 5: World Real GDP Growth Rates in % (2016-2018P): Breakdown by Country/Region (includes corresponding Graph/Chart)
2. ENDOMETRIOSIS & ITS TREATMENT - AN OVERVIEW
Introduction
Occurrence of Endometriosis in Women
Causes and Symptoms
Causes
Estrogen Theory
Müllerianosis Theory
Retrograde Menstruation Theory
Coelomic Metaplasia Theory
Hereditary Factors
Environmental Factors
Dioxin Behavior in the Body
Birth Defects
Other Causes
Symptoms of Endometriosis
Reasons for Pain due to Endometriosis
Endometriosis and Infertility
Kinds of Endometriosis
Reproductive Area Endometriosis
Uterosacral/Presacral Nerve Endometriosis
Cul-de-Sac ("Pouch of Douglas") Endometriosis
Gastrointestinal Endometriosis
Pleural (lung/chest cavity/diaphragmatic) Endometriosis
Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
Skin Endometriosis
Sciatic Endometriosis
Stages of Endometriosis
Diagnosis of Endometriosis
Major Diagnostic Techniques
Pelvic Exam
Laparoscopy
Other Diagnostic Procedures
A New Non-invasive Test for the Diagnosis of Endometriosis
Endometriosis Markers
Counseling of patients
Recurrence of Endometriosis
Endometriosis & Infertility
Miscarriage
Endometriosis & Thyroid Autoimmunity
Relationship between Endometriosis and Autoimmune Disease
Endometriosis & Cancer
Associations & Research Centers
The Endometriosis Association
Endometriosis Research Center
3. TREATMENT OF ENDOMETRIOSIS
Endometriosis & Available Treatment Options
Endometriosis Treatment Mechanisms: In a Nutshell
I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
II. Hormonal Therapy
Gonadotropin Releasing Hormone (Gnrh) Agonists
Select Major GnRH-Agonists for Endometriosis Treatment
Lupron, Zoladex and Synarel - The Major Drugs
AbbVie€™s Lupron® (Leuprorelin)
AstraZeneca€™s Zoladex® (Goserelin)
Pfizer€™s Synarel (Nafarelin Acetate)
Add-back Medication
Progestogens
Select Major Progestins for Endometriosis Treatment
Combined Oral Contraceptive Pill
Danazol and Other Suppressive Steroids
Chinese Herbs - More Effective than Danazol or Gestrinone
Aromatase Inhibitors
III. Non-hormonal Therapy
Anti-Angiogenic Agents
Selective COX-2 Inhibitors
TNF-Alpha Inhibitors
IV. Surgical Techniques
V. Complementary Therapies
Long-term Approach to Pain
Lifestyle Modifications
Chinese Herbs
Treatment for Endometriosis-related Infertility
Hormonal Treatment
Minimal to Mild Endometriosis
Moderate-Severe Endometriosis
Surgical Treatment
Minimal-Mild Endometriosis
Moderate-Severe Endometriosis
Treatment for Ovarian Endometriosis
Surgical Vs. Medicinal Interventions
Medicinal Interventions
Advantages
Disadvantages
Surgery
Advantages
Disadvantages
In-vitro Fertilization
Other Treatment
4. SELECT CLINICAL TRIALS/PRODUCT INNOVATIONS & APPROVALS
AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix
AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix
Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan€™s Efficacy in Treating Symptomatic UF
ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109
Repros Keeps Proellex® Development Program on Partial Clinical Hold of FDA
Aeterna Zentaris Halts Development of Zoptrex
Evotec and Bayer€™s Endometriosis Alliance Portfolio Advances into Phase I Clinical Development
ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2
to Treat UF
Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF
Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated Pain
Repros Therapeutics€™ Achieves Positive Results from Proellex Phase II Study
ValiRx Bags European Patent for VAL201
Virexxa Receives FDA Clearance to Proceed to Phase II
OBE2109 by ObsEva Receives IND Clearance
Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
Teleflex to Showcase its Surgical Solutions for Endometriosis
ValiRx Plc Receives Patent Grant for VAL201
5. RECENT INDUSTRY ACTIVITY
AstraZeneca Bags Commercial Rights to Zoladex
Astellas Pharma to Acquire Ogeda
Roivant Establishes New Global Headquarters in Basel
Takeda and Roivant Partner to Form Myovant
Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109
6. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie Inc. (USA)
Astellas Pharma Inc. (Japan)
AstraZeneca Plc (UK)
Bayer AG (Germany)
Debiopharm Group (Switzerland)
Evotec AG (Germany)
Kissei Pharmaceutical Co., Ltd. (Japan)
Neurocrine Biosciences, Inc. (USA)
ObsEva SA (Switzerland)
Pfizer, Inc. (USA)
Repros Therapeutics, Inc. (USA)
Roivant Sciences GmbH (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
ValiRx plc (UK)
7. GLOBAL MARKET PERSPECTIVE
Table 6: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 7: World Historic Review for Endometriosis Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2
(includes corresponding Graph/Chart)
Table 8: World 14-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2017 and 2022 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A.Market Analysis
Largest Market for Endometriosis Drugs
Endometriosis Associations Increase Awareness
Newer Diagnostic Methods Yet to Expand Across the Country
Key Endometriosis Drugs on the Market
Product Launches/Clinical Trials
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 9: The US Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 10: The US Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
2. CANADA
A.Market Analysis
Product Launch
Key Players
B.Market Analytics
Table 11: Canadian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 12: Canadian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
3. JAPAN
A.Market Analysis
Clinical Trial
Key Players
B.Market Analytics
Table 13: Japanese Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 14: Japanese Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4. EUROPE
Market Analysis
Table 15: European Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 16: European Historic Review for Endometriosis Drugs by Geographic Region/ Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2
through 2014 (includes corresponding Graph/Chart)
Table 17: European 14-Year Perspective for Endometriosis Drugs by Geographic Region/ Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2017 and 2
(includes corresponding Graph/Chart)
4a. FRANCE
A.Market Analysis
Programmes to Maintain Endometriosis Database
B.Market Analytics
Table 18: French Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 19: French Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Clinical Trials
Strategic Corporate Development
Key Players
B.Market Analytics
Table 20: German Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 21: German Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4c. ITALY
Market Analysis
Table 22: Italian Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 23: Italian Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Product Launches/Clinical Trials
Key Players
B.Market Analytics
Table 24: The UK Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 25: The UK Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4e. SPAIN
Market Analysis
Table 26: Spanish Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 27: Spanish Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
4f. REST OF EUROPE
A.Market Analysis
Product Launches/Clinical Trials
Strategic Corporate Developments
Key Players
B.Market Analytics
Table 28: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 29: Rest of Europe Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
A.Market Analysis
The Rapidly Growing Market
Endometriosis Therapeutics in Australia
B.Market Analytics
Table 30: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 31: Asia-Pacific Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
6. REST OF WORLD
A.Market Analysis
Product Launch
B.Market Analytics
Table 32: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 33: Rest of World Historic Review for Endometriosis Drugs Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 38 (including Divisions/Subsidiaries - 40) The United States (11) Canada (3) Japan (6) Europe (15) - France (1) - Germany (3) - The United Kingdom (2) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (3) Middle East (1) Latin America (1)
Read the full report: https://www.reportlinker.com/p04368326
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article